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SUMMARY 
Cytoplasmic FUS aggregates are a pathological hallmark in a subset of patients with 
frontotemporal dementia (FTD) or amyotrophic lateral sclerosis (ALS). A key step that is disrupted 
in these patients is nuclear import of FUS mediated by the import receptor 
Transportin/Karyopherin-2. In ALS-FUS patients, this is caused by mutations in the nuclear 
localization signal (NLS) of FUS that weaken Transportin binding. In FTD-FUS patients, 
Transportin is aggregated and post-translational arginine methylation, which regulates the FUS-
Transportin interaction, is lost. Here, we show that Transportin and arginine methylation have a 
crucial function beyond nuclear import, namely to suppress RGG/RG-driven phase separation and 
stress granule association of FUS. ALS-associated FUS-NLS mutations weaken the chaperone 
activity of Transportin and loss of FUS arginine methylation, as seen in FTD-FUS, promote phase 
separation and stress granule partitioning of FUS. Our findings reveal two regulatory mechanisms 
of liquid phase homeostasis that are disrupted in FUS-associated neurodegeneration. 
 
 
KEYWORDS 
ALS, arginine methylation, FTD, Fused in Sarcoma (FUS), Karyopherin-2 (Kap2), phase 
transition, neurodegeneration, nuclear import, stress granules, Transportin (TNPO1) 
  
3 
 
INTRODUCTION 
Protein aggregates are a pathological hallmark of all neurodegenerative diseases and are thought 
to drive the process of neurodegeneration (Taylor et al., 2002). In ALS (amyotrophic lateral 
sclerosis) and FTD (frontotemporal dementia), the major aggregating proteins are two ubiquitously 
expressed RNA-binding proteins (RBPs) called TDP-43 (TAR DNA binding protein of 43 kDa) 
and FUS (Fused in sarcoma) (Neumann et al., 2009; Neumann et al., 2006). TDP-43 and FUS are 
enriched in the cell nucleus, but in post mortem brains and spinal cords of ALS/FTD patients they 
are often absent from the nucleus and are found in cytoplasmic aggregates in neuronal and 
sometimes glia cells (Mackenzie et al., 2010). RBP aggregation is thought to cause widespread 
disturbances in neuronal RNA metabolism and neurodegeneration, by loss- and/or gain-of-function 
mechanisms (Ling et al., 2013). How cytosolic RBP aggregation arises and which cellular quality 
control mechanisms help to prevent it is not well understood. 
A key pathomechanism in ALS/FTD cases with FUS aggregates is defective nuclear import. 
Mutations in FUS that cause familial ALS (ALS-FUS) (Kwiatkowski et al., 2009; Vance et al., 
2009) often alter or entirely delete the C-terminal nuclear localization signal (NLS) and thus impair 
nuclear import of FUS (Dormann et al., 2010). The NLS consists of a C-terminal proline tyrosine 
(PY)-NLS (Lee et al., 2006) and the preceding arginine/glycine-rich RGG3 domain (Dormann et 
al., 2012). Both domains interact with the nuclear import receptor Transportin (TNPO1) / 
Karyopherin 2 (Kap2) (Lee et al., 2006), which translocates FUS across the nuclear pore 
complex into the nucleoplasm. Reduced TNPO1 binding and impaired nuclear import of FUS is 
pathogenic, as FUS mutations that lead to severely reduced TNPO1 binding cause early ALS onset 
and rapid disease progression (Dormann et al., 2010). This phenotype was recently modelled in 
mice, where FUS-NLS mutations cause motor neuron degeneration (Devoy et al., 2017; Scekic-
Zahirovic et al., 2017). 
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Defective nuclear import also plays a role in FTD cases with FUS pathology (FTD-FUS), 
which are usually not associated with FUS mutations (Snowden et al., 2011). In these cases, 
TNPO1 is aggregated and partially detergent-insoluble (Brelstaff et al., 2011; Neumann et al., 
2012). Moreover, arginine methylation (arg-methylation), which regulates TNPO1 binding and 
nuclear import of FUS, is defective in FTD-FUS patients (Dormann et al., 2012; Suarez-Calvet et 
al., 2016). Arg-methylation is a common post-translational modification (PTM) in nuclear RBPs, 
often regulating their nuclear localization as well as protein-protein or protein-RNA interactions 
(Bedford and Clarke, 2009). Arg-methylation is carried out by protein arginine methyl-transferases 
(PRMTs), which transfer one or two methyl groups from S-adenosyl-methionine (SAM) onto the 
arginine side chain (Yang and Bedford, 2013). FUS contains three arginine-glycine-glycine (RGG) 
repeat domains with RGG/RG motifs that are extensively modified with asymmetric dimethyl 
groups by PRMT1 or PRMT8 (Ong et al., 2004; Scaramuzzino et al., 2013). We have previously 
shown that arginine dimethylation is lost in FTD-FUS patients. Instead, deposited FUS is un- or 
monomethylated (Dormann et al., 2012; Suarez-Calvet et al., 2016). However, it is still unclear 
whether loss of FUS arg-methylation is pathogenic and contributes to FUS dysfunction or 
aggregation. 
We and others have previously proposed that FUS aggregation is initiated in stress granules 
(SGs), as ALS-associated FUS-NLS mutations cause an accumulation of FUS in SGs and FUS 
aggregates in ALS/FTD post mortem brains often contain SG marker proteins (Dormann et al., 
2010; Li et al., 2013). Thus, SGs or other ribonucleoprotein (RNP) granules may act as 
condensation sites, where aggregation-prone RBPs start to aggregate once they exceed a critical 
concentration. Recently, it has been shown that FUS and related RBPs undergo concentration-
dependent, reversible liquid-liquid phase separation (LLPS) in vitro, i.e. they form liquid-like 
protein droplets that have similar dynamic properties as cellular RNP compartments. Over time, 
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liquid FUS and hnRNP-A1 droplets undergo an irreversible “liquid-to-solid phase transition” and 
form solid, fibrous aggregates in vitro (Molliex et al., 2015; Patel et al., 2015). LLPS and liquid-
to-solid phase transition of FUS is concentration-dependent (Patel et al., 2015), hence the high 
local concentration of FUS in SGs may promote LLPS and solidification of FUS. 
In the case of FUS, LLPS and aggregation are reported to be largely driven by the N-
terminal SYGQ-rich domain (Burke et al., 2015; Kato et al., 2012; Murakami et al., 2015; Patel et 
al., 2015; Sun et al., 2011), which has a similar amino acid composition as yeast prion domains 
(King et al., 2012). Here, we show that the C-terminal RGG3-PY domain and arginines in RGG 
motifs of FUS are also crucial for phase separation of FUS. We demonstrate that TNPO1, which 
directly interacts with arginines in the RGG3-PY domain, acts as a FUS chaperone and suppresses 
phase separation and SG association of FUS. Furthermore, we establish that arg-methylation of 
FUS reduces LLPS and SG association of FUS, suggesting that loss of arg-methylation, as seen in 
FTD-FUS patients, is pathogenic by directly promoting FUS aggregation. Finally, we show that 
the ALS-associated FUS-P525L mutation renders the protein less sensitive to the chaperone 
activity of TNPO1 and hence not only impairs nuclear import, but also enhances phase separation 
and SG accumulation of mutant FUS. Our findings reveal two novel regulatory mechanisms of 
liquid phase homeostasis that are disrupted in FUS-associated ALS and FTD. This supports the 
view that phase separation and SG accumulation of FUS are crucially involved in ALS/FTD 
pathogenesis.   
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RESULTS 
Transportin suppresses phase transitions of FUS in vitro 
As several Importin Imp-type nuclear import receptors were shown to act as cytoplasmic 
chaperones of positively charged ribosomal proteins and histones (Jakel et al., 2002), we 
hypothesized that TNPO1 may exert a similar function towards other positively charged import 
cargoes, including FUS. To test whether TNPO1 affects phase transitions of FUS, we purified 
MBP-FUS-EGFP-His6 and MBP-FUS-His6 (see scheme in Fig. S1A) from E.coli. At physiological 
FUS concentrations, both proteins were soluble and dispersed, whereas proteolytic removal of the 
MBP- tag with TEV protease caused them to phase separate and form numerous liquid-like droplets 
(Fig. 1A, Fig. S1B). To verify that droplet formation was not induced by TEV protease 
independently of proteolytic cleavage, we used MBP-FUS containing a PreScission cleavage site, 
which only formed droplets upon addition of PreScission protease, but not upon addition of TEV 
protease (Fig. S1B). 
To assess how TNPO1 affects LLPS of FUS, we added equimolar amounts of purified 
TNPO1 or buffer only to MBP-FUS-EGFP and monitored TEV cleavage-induced FUS droplet 
formation. Strikingly, droplet formation was significantly suppressed by TNPO1 (Fig. 1A, see B 
for quantification). Moreover, when TNPO1 was added to preformed FUS droplets, they 
immediately dissolved (Fig. S1C), indicating that TNPO1 is able to reverse LLPS of FUS. Two 
other direct FUS interactors (Fig. S1D), PRMT1 (Scaramuzzino et al., 2013) and an anti-FUS-
RGG3-specific antibody (Suarez-Calvet et al., 2016), were unable to suppress FUS droplet 
formation to the same degree as TNPO1 (Fig. 1A, B). Likewise, the nuclear import receptor 
Importin 5 (Imp5), which is not the cognate importin of FUS and does not bind to FUS in vitro 
(Fig. S1D), also did not suppress LLPS of FUS (Fig. 1A, B). 
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Next, we monitored phase separation of non-EGFP-tagged FUS in a turbidity assay, where 
the optical density of the protein solution is used as a measure of phase separation. The solution 
became turbid upon TEV cleavage of MBP-FUS in the presence of buffer, PRMT1, anti-FUS-
RGG3 antibody or Imp5, whereas turbidity remained low in the presence of TNPO1 (Fig. 1C). 
Second, we used a sedimentation assay, where samples are centrifuged and partitioning of FUS 
into the pellet fraction is used as a measure of phase separation. Upon TEV cleavage, FUS 
quantitatively entered the pellet fraction, but remained mainly in the supernatant when TNPO1 was 
present (Fig. 1D, see Fig. 1E for quantification). In contrast, PRMT1, the FUS-RGG3-specific 
antibody or Imp5 were unable to prevent partitioning of FUS into the pellet fraction. 
Finally, we performed in vitro “aging” experiments, in which liquid FUS droplets are 
incubated for a few hours with mild agitation and thus are converted into large amorphous 
aggregates over time (Patel et al., 2015). Addition of TNPO1, but not PRMT1 or Imp5, prevented 
formation of amorphous FUS-EGFP structures that normally formed during in vitro aging (Fig. 
1F). Similarly, after a 90 min in vitro incubation of TEV-cleaved MBP-FUS, transmission electron 
microscopy revealed the presence of rod-like FUS fibrils, which was prevented in the presence of 
TNPO1 (Fig. 1G). 
Together, these results demonstrate that TNPO1 appears to have a dual function and not 
only mediates nuclear import of FUS, but also acts as a chaperone and suppresses LLPS and 
consequent solidification of FUS in vitro. 
 
Transportin reduces SG association of FUS, independent of its nuclear import activity 
TNPO1 is expected to exert its chaperone function towards FUS mainly in the cytoplasm, where 
RanGTP levels are low and TNPO1 binds tightly to PY-NLS-containing cargoes (Lee et al., 2006). 
To test whether TNPO1 indeed acts a chaperone of FUS in cells, we expressed a cytosolically 
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anchored version of FUS (GCR2-tagRFP2-FUS) in HeLa cells. This fusion protein is retained in 
the cytoplasm by a hormone-responsive domain of the glucocorticoid receptor (GCR) (Love et al., 
1998). We interfered with FUS-TNPO1 binding by co-expressing a peptide inhibitor of TNPO1, 
EGFP-M9M, which binds TNPO1 with unnaturally high affinity and competes with natural 
TNPO1 cargoes (Cansizoglu et al., 2007). As a control, we expressed an Importin alpha (Imp -
specific high affinity peptide inhibitor (EGFP-bimax), which interferes with Imp -cargo binding 
and Imp -dependent nuclear import (Kosugi et al., 2008). In cells expressing bimax, 
cytosolically anchored FUS remained diffusely distributed, whereas in cells expressing M9M, FUS 
was localized in TIA1-positive SGs in a significant number of cells (Fig. 2A, B). Note that M9M-
expressing cells had similar or lower expression levels of GCR2-tagRFP2-FUS than bimax-
expressing cells (data not shown). This suggests that impaired FUS-TNPO1 binding favors 
partitioning of cytosolic FUS into SGs. 
To directly test the hypothesis that TNPO1 suppresses SG association of FUS, we utilized 
a modified version of the semi-permeabilized cell assay that is routinely used to study nuclear 
transport of proteins under defined conditions (Adam et al., 1990). We elicited SGs by treating 
HeLa cells with the proteasome inhibitor MG132, then selectively permeabilized the plasma 
membrane using digitonin and washed out soluble factors, including importins (see scheme in Fig. 
2C). To focus only on the cytosolic function of TNPO1, we prevented nuclear import by blocking 
nuclear pores with wheat germ agglutinin (WGA) (Yoneda et al., 1987). Upon addition of MBP-
FUS-EGFP to semi-permeabilized cells, the protein specifically associated with G3BP1-positive 
SGs (Fig. 2D). Consistent with our hypothesis, SG association was significantly reduced when 
TNPO1 was added together with FUS (Fig. 2D, E). 
 In summary, our data show that TNPO1 reduces partitioning of FUS into SGs independent 
of its nuclear import activity. This demonstrates that TNPO1 not only suppresses phase transitions 
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of FUS in vitro, but also acts as a FUS chaperone in the cytoplasm, thus reducing the risk of aberrant 
FUS phase transitions in SGs. 
 
C-terminal RGG/RG motifs are crucial for phase separation of FUS 
FUS contains extended disordered LC domains, including the N-terminal SYGQ-rich domain and 
C-terminal RGG domains enriched in RGG/RG motifs (Fig. 3A). Even though LLPS and 
aggregation of FUS is thought to be largely driven by the N-terminal SYGQ-rich domain (Kato et 
al., 2012; Patel et al., 2015; Sun et al., 2011), there is evidence that C-terminal regions, in particular 
RGG/RG-rich domains, contribute to phase separation and aggregation of FUS (Boeynaems et al., 
2017; Schwartz et al., 2013). As TNPO1 binds to the C-terminal RGG3-PY domain, we speculated 
that this domain critically contributes to phase separation of FUS and that TNPO1 may achieve 
chaperoning of FUS by interacting with LLPS-promoting RGG/RG motifs. 
To test this hypothesis, we purified the C-terminal RGG3-PY domain (see Fig. S2A for 
sequence) from E.coli and tested its ability to phase separate. In the presence of substoichiometric 
amounts of RNA, RGG3-PY formed liquid droplets in a concentration- and temperature-dependent 
manner (Fig. 3B and Fig. S2B), similar to the N-terminal SYGQ-rich domain (Burke et al., 2015). 
Formation of RGG3-PY droplets was enhanced at lower salt concentrations (Fig. S2C), suggesting 
that electrostatic interactions involving RGG/RG motifs drive LLPS of this domain. To investigate 
the importance of arginines in LLPS of RGG3-PY, we expressed and purified a mutant version, 
termed KGG3-PY, in which all arginines in RGG motifs were replaced by lysine (K) (see Fig. 
S2A). Strikingly, KGG3-PY remained completely dispersed and did not form any visible droplets 
under conditions that induced large RGG3-PY droplets (Fig. 3B). This demonstrates that arginines 
in RGG motifs are crucial for LLPS of the RGG3-PY domain. 
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To test whether the C-terminal RGG3-PY domain and arginine residues in RGG/RG motifs 
are important for phase separation of full-length FUS, we purified two mutant versions of MBP-
FUS, where we either deleted the C-terminal RGG3-PY domain (RGG3-PY) or mutated all 
arginines in RGG/RG motifs to lysine (all-KGG) (see Fig. S2D for Western blot characterization). 
In a turbidity assay, FUS-wild-type (WT) showed a strong turbidity increase, whereas FUS-
RGG3-PY yielded lower turbidity values and the all-KGG mutant failed to become turbid at all 
(Fig. 3C). Sedimentation analysis confirmed that RGG3-PY shows reduced partitioning into the 
pellet fraction compared to FUS-WT, and the all-KGG mutant remained mostly soluble (Fig. 3D, 
E). Thus, phase separation of FUS not only requires the N-terminal SYGQ-rich domain, but also 
arginine residues in C-terminal RGG/RG motifs. 
 
Molecular mechanisms contributing to chaperoning of FUS by TNPO1 
Based on this finding, we considered two mutually not exclusive hypotheses as to how TNPO1 
may suppress LLPS of FUS: First, as RGG/RG motifs were shown to be crucial for RNA-binding 
of FUS (Ozdilek et al., 2017), we considered the possibility that TNPO1 may compete with RNA-
binding to RGG/RG motifs and hence suppress RNA-driven LLPS of FUS. Second, TNPO1 may 
directly interact with arginines and thus interfere with arginine-driven LLPS of FUS. 
To address the first hypothesis, we performed NMR spectroscopy and examined the effect 
of TNPO1 on RNA-driven phase separation of the RGG3-PY domain: Addition of increasing 
amounts of unlabeled RNA to 15N-labeled RGG3-PY caused the sample to become turbid (data not 
shown) and led to progressive disappearance of 1H-15N cross peaks (Fig. S2E) and decreased signal 
intensity in the corresponding 1D NMR spectra (Fig. S2F). This is in agreement with the formation 
of high-molecular weight RGG3-PY/RNA droplets, leading to broadening of NMR signals due to 
the decreased rotational tumbling time of the RGG3 region within droplets. RNA was 
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quantitatively bound by RGG3-PY droplets, as NMR signals of unlabeled RNA were absent in the 
1D NMR spectra (Fig. S2F). Addition of TNPO1 to the RGG3-PY/RNA droplet sample led to 
reappearance of the RNA 1H NMR signals (Fig. S2F) and a loss of turbidity, indicating that TNPO1 
binding displaces the RNA from RGG3-PY and results in droplet dissolution. Concordantly, 
radioactive filter binding experiments demonstrated that RNA is displaced from full-length FUS 
upon addition of TNPO1 (Fig. 3F). However, in the turbidity assay we did not detect an altered 
phase separation behavior of full-length FUS upon titrating in ASH1 E3-51 RNA (Fig. 3G); similar 
results were obtained for MAPT RNA and total RNA (data not shown). This suggests that phase 
separation of full-length FUS is not strongly affected by RNA under our experimental conditions. 
Hence, the displacement of RNA from FUS might not be the major mechanism by which TNPO1 
suppresses phase separation of FUS. 
In support of the second hypothesis, namely that TNPO1 interferes with phase separation 
of FUS by interacting with arginines in the C-terminal RGG3-PY domain, we have previously 
shown that TNPO1 directly binds to a synthetic FUS-RGG3 peptide (Dormann et al., 2012) and to 
several arginine residues in the FUS-RGG3 region (R472, R473, R476) (Gobl et al., 2016). This 
interaction appears to be mainly charge-driven, as we observed a strong decrease in binding of 
TNPO1 to RGG3-PY at higher salt concentration (Fig. S4A, Table S1). Together, our previously 
published data and our ITC results show that electrostatic interactions and arginine residues play a 
key role in binding of RGG3-PY to TNPO1. As arginine residues and the C-terminal RGG3-PY 
domain of FUS appear to be crucial for phase separation of FUS (Fig. 3B-E), we propose that direct 
binding of TNPO1 to arginines in the RGG3-PY domain interferes with arginine-driven phase 
separation of FUS and thus could be an important component of the chaperoning mechanism. 
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Arginine methylation reduces LLPS and SG association of FUS 
As arginines in RGG/RG motifs have an important contribution to LLPS of FUS (Fig. 3B-E), we 
asked how arg-methylation alters phase separation of FUS. This question is of great interest, as 
arg-dimethylation of the FUS-RGG3 domain is lost in FTD-FUS patients (Dormann et al., 2012; 
Suarez-Calvet et al., 2016), but it is unclear whether and how loss of FUS methylation is 
pathogenic. 
To address this question, we in vitro methylated purified MBP-FUS-EGFP, MBP-FUS or 
RGG3-PY by adding the purified arginine methyl transferase PRMT1 and SAM as a methyl donor 
(Fig. S3A). FUS proteins were purified from bacteria and therefore were originally unmethylated. 
After incubation with PRMT1 and SAM, all three proteins were efficiently converted from an un- 
to a dimethylated form, but remained unmethylated upon incubation with PRMT1 only (Fig. S3B, 
similar results for MBP-FUS and RGG3-PY, data not shown). First, we examined the propensity 
of unmethylated and methylated MBP-FUS-EGFP to undergo LLPS and found that unmethylated 
FUS formed liquid droplets at lower concentrations than dimethylated FUS (Fig. 4A). This 
difference was not caused by the methyl donor SAM, as addition of SAM alone did not alter droplet 
formation (data not shown). Compared to dimethylated FUS, unmethylated FUS also showed 
reduced internal mobility within the dense droplet phase, as measured by fluorescence recovery 
after photobleaching (FRAP) following a “half-bleach” of FUS-EGFP droplets (Fig. 4B, C). 
Moreover, in a turbidity assay, unmethylated FUS reached higher turbidity values than methylated 
FUS (Fig. 4D). Sedimentation analysis confirmed that unmethylated FUS had a higher propensity 
to partition into the pellet fraction compared to methylated FUS (Fig. S3C, D). Enhanced phase 
separation was also observed for the unmethylated RGG3-PY domain, which reached higher 
turbidity values than methylated RGG3-PY upon addition of RNA (Fig. S3E). This difference was 
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not due to altered RNA-binding, as filter binding experiments demonstrated equal affinity of 
unmethylated and methylated RGG3-PY for RNA (Fig. S3F, G, Table S2). 
To transfer these findings into cells, we investigated whether arg-methylation affects SG 
association of FUS in the semi-permeabilized cell assay. Indeed, unmethylated FUS showed a 
higher association with G3BP1-positive SGs compared to the methylated protein (Fig. 4E, F). This 
suggests that unmethylated FUS associates with SGs more stably than methylated FUS. In 
conclusion, loss of FUS arg-methylation, as seen in FTD-FUS patients, promotes LLPS and SG 
partitioning of FUS and thus may contribute to FUS aggregation in FTD-FUS patients. 
 
The ALS-associated FUS-P525L mutation renders FUS less sensitive to the chaperone 
activity of TNPO1  
Most ALS patients with FUS pathology carry a mutation in the PY-NLS, which causes reduced 
binding to TNPO1 and impairs nuclear import of FUS (Dormann et al., 2010; Zhang and Chook, 
2012). Given our finding that TNPO1 suppresses LLPS and SG association of FUS, we 
hypothesized that FUS PY-NLS mutations may also impair chaperoning of FUS by TNPO1 and 
thus promote aberrant phase transitions and SG partitioning of mutant FUS. 
To test this hypothesis, we purified MBP-FUS-EGFP and the RGG3-PY domain with an 
intact or mutant (P525L) PY-NLS. The P525L mutation severely weakens TNPO1 binding (Zhang 
and Chook, 2012) and causes early onset ALS and rapid disease progression (Chio et al., 2009). 
As the FUS-RGG3 domain is normally arg-methylated in ALS-FUS patients and this furthermore 
weakens TNPO1 binding (Dormann et al., 2012) (Table S1, Fig. S4A, B), we in vitro methylated 
WT and mutant proteins (Fig. S4C) and then examined their ability to phase separate in the 
presence and absence of TNPO1. Without TNPO1, mutant and WT proteins formed liquid droplets 
to a similar extent (Fig. 5A, B), hence the P525L mutation does not alter LLPS of FUS under these 
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conditions. In line with our hypothesis, the WT protein was efficiently chaperoned by TNPO1, 
whereas the mutant protein still formed liquid droplets in the presence of TNPO1, even after 
prolonged incubation (8h) (Fig. 5A, B). 
To test whether the P525L mutation also causes reduced chaperoning by TNPO1 in cells, 
we examined the ability of TNPO1 to suppress SG association of WT vs. mutant MBP-FUS-EGFP 
in the semi-permeabilized cell assay. Both WT and mutant protein showed a similar SG association, 
however addition of TNPO1 reduced SG partitioning of the WT protein, but was significantly less 
efficient in chaperoning the P525L mutant protein (Fig. 5C, D). This was not due to better nuclear 
import of the WT protein, as nuclear pores were blocked in this assay by WGA. 
Finally, we tested whether the P525L mutation favors SG partitioning of FUS in intact and 
living cells, independent of reduced nuclear import. To do so, we used the GCR-based cytosolic 
anchoring system and expressed GCR2-tagRFP2-tagged FUS-WT or P525L in HeLa cells. Both 
fusion proteins are localized in the cytoplasm (Fig. 5E) and reached similar expression levels (data 
not shown). In cells where G3BP1-positive SGs were elicited due to transfection stress, the WT 
protein was predominantly diffusely distributed in the cytoplasm and showed little SG association, 
whereas the P525L mutant protein frequently co-localized with G3BP1-positive SGs (Fig. 5E, F). 
Together, our in vitro and cellular data show that ALS-associated FUS-NLS mutations that 
strongly reduce TNPO1 binding not only impair nuclear import of FUS, but also render the protein 
less sensitive to the chaperoning activity of TNPO1. Hence, such mutations have an unexpected 
novel pathomechanism and favor aberrant phase transitions and SG partitioning of mutant FUS in 
the cytoplasm.  
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DISCUSSION 
The nuclear import receptor TNPO1 acts as a cytoplasmic chaperone of FUS 
FUS is among the top 5% of proteins in terms of protein abundance (Wisniewski et al., 2014), 
hence its cellular concentration (~2 - 10 µM) is close to the critical concentration where purified 
FUS undergoes LLPS and liquid-to-solid phase transition in vitro (Patel et al., 2015). This suggests 
that efficient protein quality control (PQC) mechanisms prevent such aberrant phase transitions in 
cells. Our data demonstrate that TNPO1 fulfills such a PQC function and suppresses aberrant phase 
transitions of FUS in vitro and in the cytoplasm and decreases the potentially detrimental 
accumulation of FUS in SGs. SGs are thought to be the sites where FUS (and other aggregation-
prone RBPs) get highly concentrated and thus undergo concentration-dependent LLPS and 
aggregation (Alberti and Hyman, 2016). The importance of SGs for RBP aggregation is 
underscored by the observation that FUS and TDP-43 aggregates in ALS and FTD patients contain 
various SG marker proteins (Bentmann et al., 2012; Dormann et al., 2010) and that ALS-causing 
mutations in FUS or other RBPs promote SG localization or alter SG dynamics (Kim et al., 2013; 
Mackenzie et al., 2017). Our data show that (i) impaired FUS-TNPO1 binding in cells promotes 
SG localization of FUS and that (ii) TNPO1 directly reduces SG partitioning of FUS. This activity 
of TNPO1 is independent of its nuclear import function, as nuclear import of FUS was blocked in 
our cellular assays. Interestingly, TNPO1 and other importins are found in SGs and P bodies 
(Chang and Tarn, 2009; Fujimura et al., 2010; Weinmann et al., 2009). Our data suggest that 
chaperoning of aggregation-prone RBPs may be one important function of importins in 
cytoplasmic RNP granules. 
Importins may have a general chaperone function towards aggregation-prone basic proteins, 
as several other Imp -type nuclear import receptors were shown to prevent aggregation of basic 
ribosomal proteins and histones (Jakel et al., 2002). As importins are similarly abundant as heat 
16 
 
shock proteins, they appear suited to shield basic stretches on abundant import cargoes, including 
ALS/FTD-associated RBPs. Indeed, Imp  prevents and reverses TDP-43 fibrillization and 
TNPO1 also inhibits and reverses fibrillization of the PY-NLS-containing cargoes EWS, TAF15, 
hnRNP-A1 and hnRNP-A2 (see Guo et al., Cell this issue). 
 
Arginines in RGG/RG motifs are crucial for phase separation of FUS 
So far, LLPS and aggregation of FUS were thought to be primarily driven by the N-terminal 
SYGQ-rich domain (Burke et al., 2015; Kato et al., 2012; Murakami et al., 2015; Patel et al., 2015; 
Sun et al., 2011). Our data now show that the C-terminal RGG3-PY domain and, in particular, 
arginines in RGG/RG motifs also play a crucial role in phase separation of FUS. Our findings are 
consistent with the previous reports that the RGG2-ZnF-RGG3 domain of FUS forms fibrous 
assemblies in vitro (Schwartz et al., 2013) and that a synthetic FUS-RGG3 peptide forms droplets 
in the presence of a molecular crowder or polyU30 (Boeynaems et al., 2017). RGG/RG-rich 
sequences were also shown to drive phase separation of the C.elegans P granule proteins LAF-1 
and PGL-3 and the human RNA helicases Ddx4, DDX3X and EIF4H (Elbaum-Garfinkle et al., 
2015; Nott et al., 2016; Nott et al., 2015; Saha et al., 2016). Moreover, arginine-rich dipeptide 
repeat (DPR) proteins derived from expanded C9orf72 hexanucleotide repeats phase separate in 
vitro (Boeynaems et al., 2017). In the Ddx4 disordered domain, repeatedly spaced RG/GR and 
FG/GF dipeptides, suggested to engage in arginine-aromatic (cation-) interactions, were shown 
to drive LLPS and droplet formation (Nott et al., 2015). The RGG3-PY domain contains a similar 
sequence pattern (Fig. S2A), with multiple RGG, RG/GR motifs as well as (F/Y)G or G/(F/Y) 
dipeptides. As tyrosine (Y) residues in the N-terminal SYGQ-rich domain of FUS were shown to 
drive hydrogel formation (Kato et al., 2012) and to promote phase separation of a poly-SH3 domain 
(Lin et al., 2017), it can be speculated that both N-terminal tyrosines and C-terminal arginines 
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crucially contribute to phase separation of FUS and possibly promote LLPS by engaging in 
tyrosine-arginine (cation-) interactions. 
 
Multiple mechanisms may contribute to the chaperone activity of TNPO1 
So far, TNPO1 was shown to bind to the FUS-PY-NLS (Zhang and Chook, 2012) and the 
neighboring RGG3 domain as additional binding epitope (Dormann et al., 2012, Gobl et al., 2016). 
As arginines in RGG/RG motifs are crucial for efficient phase separation of FUS, we propose that 
direct TNPO1-arginine interactions contribute to chaperoning of FUS by TNPO1. By directly 
interacting with arginines, TNPO1 may suppress weak intermolecular interactions of arginines with 
other residues (e.g. cation- interactions) that drive LLPS of FUS, thus suppressing arginine-driven 
phase transitions. 
Beyond this arginine shielding mechanism, weak interactions of TNPO1 with other FUS 
domains, e.g. the N-terminal SYGQ-rich domain or folded RNA-binding domains (RRM and zinc 
finger domain) (see Yoshizawa et al., Cell, this issue), may also contribute to the chaperoning 
activity of TNPO1. It can be speculated that TNPO1 not only has the ability to break weak transient 
intermolecular interactions between FG-rich nucleoporins as it traverses the nuclear pore, but can 
also engage in multiple low affinity interactions with different sites of NLS-bound cargo proteins, 
to keep them soluble in the cytoplasm and during transport. TNPO1-binding to different RNA-
binding domains could underlie the RNA displacement that we observed upon addition of TNPO1 
to FUS. As RNA has been reported to promote LLPS and aggregation of FUS (Burke et al., 2015; 
Schwartz et al., 2013), it seems possible that a displacement of RNA by TNPO1 may additionally 
contribute to the chaperoning mechanism. As we did not find a promoting effect of different types 
of RNA on phase separation of full-length FUS in our turbidity assay, the exact role of RNA in 
LLPS and aggregation of FUS needs for be clarified in future studies. Nevertheless, the 
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displacement of RNA from FUS by TNPO1 may have an important function in the cell and ensure 
that RBPs, such as FUS, are imported in an RNA-free form, thus preventing mRNA reimport into 
the cytoplasm. Moreover, it may help to release mRNAs from RBPs for local translation, as 
reported for the yeast homologue of TNPO1, Kap104p (van den Bogaart et al., 2009). 
 
Arginine methylation reduces LLPS and SG association of FUS 
In line with the idea that RGG/RG motifs are crucially involved in phase separation of FUS, we 
found that arg-methylation of RGG/RG motifs reduces LLPS of FUS and increases droplet 
dynamics. A similar effect has been reported for the disordered Ddx4 domain and the LC domain 
of hnRNP-A2 (Nott et al., 2015; Ryan et al., 2018). Although arg-methylation does not alter the 
positive net charge, it changes hydrogen bonding and local hydrophobicity of arginines (Fuhrmann 
et al., 2015) and thus may influence cation- interactions that drive LLPS. It seems likely that 
LLPS of many more proteins is influenced by arg-methylation, as RGG/RG-rich domains appear 
to be an important determinant of LLPS and there are >400 proteins with tri- or di-RGG or tri-RG 
motifs in the human proteome, many of which are arg-methylated (Thandapani et al., 2013). 
Prominent examples could be the other two members of the FET (FUS, EWS, TAF15) family, 
EWS and TAF15, which co-aggregate with FUS in FTD-FUS patients (Neumann et al., 2011) and 
members of the hnRNP-A family, which form pathological aggregates in rare familial forms of 
ALS or the related disorder multisystem proteinopathy (Kim et al., 2013; Mori et al., 2013). It will 
be interesting to see whether arg-methylation is a PTM that generally reduces overly tight 
interactions between RGG/RG-rich low complexity domains and thus suppresses aberrant LLPS 
and aggregation of RGG/RG-rich RBPs. 
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Distinct pathomechanisms in FTD-FUS and ALS-FUS promote phase separation and SG 
localization of FUS 
We have previously shown that aggregated FUS is un- and monomethylated in FTD-FUS patients, 
whereas it carries arg-dimethyl groups in healthy cells and ALS-FUS patients (Dormann et al., 
2012; Suarez-Calvet et al., 2016). We now show that loss of FUS methylation promotes LLPS and 
SG partitioning of FUS, suggesting that the altered FUS methylation pattern is a pathogenic factor 
that contributes to the formation of FUS aggregates in patients. What remains to be clarified is why 
TNPO1 is unable to suppress pathological LLPS and aggregation of hypomethylated FUS in FTD-
FUS patients. Efficient chaperoning of hypomethylated FUS by TNPO1 would be expected, as un- 
and monomethylated FUS show a higher TNPO1 binding affinity than dimethylated FUS 
(Dormann et al., 2012; Suarez-Calvet et al., 2016) (Table S1, Fig. S4) and LLPS of unmethylated 
FUS is efficiently suppressed by TNPO1 (this study and Yoshizawa et al. and Guo et al.). One 
explanation could be that TNPO1 is aggregated and partially detergent-insoluble in post mortem 
brains of FTD-FUS patients (Brelstaff et al., 2011; Neumann et al., 2012) and hence is most likely 
functionally impaired. Cells with TNPO1 aggregates may have reduced TNPO1 activity, causing 
impaired nuclear import, enhanced LLPS and SG partitioning of FUS in the cytoplasm. It can be 
speculated that loss of FUS methylation may be a compensatory mechanism to increase TNPO1 
affinity and thus compensate for reduced TNPO1 activity. How TNPO1 becomes aggregated and 
how FUS methylation is lost in FTD-FUS patients is unknown. Addressing how TNPO1 levels and 
FUS methylation are normally regulated and how they can be modulated in cells will be important 
next steps and may lead to novel therapeutic approaches. 
In contrast to FTD-FUS, ALS-FUS patients show a normal methylation pattern (Dormann 
et al., 2012), however they often carry a FUS PY-NLS mutation, which reduces TNPO1 binding 
and impairs nuclear import of FUS (Dormann et al., 2010; Zhang and Chook, 2012). Our study, as 
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well as an accompanying study by Guo et al., now show that FUS PY-NLS mutations that severely 
reduce TNPO1 binding, such as P525L and R495X, also reduce the capacity of TNPO1 to act as a 
chaperone of FUS. Hence, ALS-associated FUS PY-NLS mutations impart a “double hit” and drive 
(i) cytosolic accumulation due to impaired nuclear import and (ii) LLPS and aggregation of FUS 
in the cytoplasm. 
 
Conclusion 
Together, our data reveal two novel mechanisms of liquid phase homeostasis, (i) arginine 
methylation and (ii) TNPO1 binding. They both suppress phase separation and SG partitioning of 
FUS and are disrupted in FTD-FUS and ALS-FUS, respectively. These findings support the view 
that phase separation and the accumulation of FUS in SGs crucially contribute to the pathogenesis 
of FUS-associated ALS and FTD. Interestingly, a similar pathomechanism has recently been 
suggested to underlie the most frequent genetic cause of ALS/FTD, a hexanucleotide repeat 
expansion in the C9orf72 gene (Edbauer and Haass, 2016), in which arginine-rich dipeptide repeat 
proteins (poly-PR, poly-GR) were shown to undergo LLPS, bind numerous LC domain-containing 
proteins, disturb LLPS of LC domain-containing proteins and alter formation and dynamics of 
membrane-less organelles, such as SGs and nucleoli (Boeynaems et al., 2017; Lee et al., 2016). 
Thus, disturbed phase transitions appear to be a common theme in ALS/FTD and possibly other 
RBP-linked disorders.  
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MAIN FIGURE TITLES AND LEGENDS 
 
Figure 1: TNPO1 suppresses phase transitions of FUS in vitro. 
(A) Droplet formation of 7 µM MBP-FUS-EGFP upon TEV cleavage is suppressed by TNPO1, 
but not by PRMT1, Imp5 or a monoclonal antibody specific for FUS-RGG3. Bar, 10 µm. 
(B) Quantification of FUS-EGFP droplets. Values represent means  SEM (n=3). ***p < 0.001 by 
one-way ANOVA with Dunnett´s multiple comparison test. 
(C) Turbidity assay to quantify phase separation of 7 µM MBP-FUS upon TEV cleavage ± TNPO1, 
PRMT1, Imp5 or anti-FUS-RGG3 antibody, respectively. Values represent means  SEM (n=3). 
***p < 0.001 by one-way ANOVA with Dunnett´s multiple comparison test. 
(D) Sedimentation assay to quantify phase separation of MBP-FUS after TEV-cleavage ± TNPO1 
or control proteins (Imp5, anti-FUS-RGG3 antibody or PRMT1). 
(E) Quantification of FUS levels in supernatant (S) and pellet (P) fractions as S/P ratio. Values 
represent mean  SEM (n=3). ***p < 0.001 by one-way ANOVA with Dunnett’s multiple 
comparison test. 
(F) TNPO1 prevents LLPS and consequent liquid-to-solid phase transition of FUS-EGFP droplets 
(7 µM) in an in vitro aging assay. Bar, 50 µm. 
(G) 7 µM MBP-FUS was incubated for 90 min with TEV protease ± TNPO1 and processed for 
TEM. Arrows indicate fibrillary FUS assemblies formed upon TEV cleavage. Bar, 200 nm. 
See also Fig. S1. 
 
Figure 2: TNPO1 acts as a FUS chaperone in cells and suppresses SG association of FUS. 
(A) Overexpression of the TNPO1-specific inhibitor EGFP-M9M, but not the Imp -specific 
inhibitor EGFP-bimax results in SG association of cytosolically anchored FUS (GCR2-tagRFP2-
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FUS, displayed in green; EGFP displayed in magenta). SGs were identified by TIA1-
immunostaining (in red). Nuclei were counterstained with DAPI (turquoise). Bar, 20 µm. 
(B) Quantification of cells with GCR2-tagRFP2-FUS in SGs upon co-expression of either EGFP-
bimax or -M9M. Values represent mean  SEM (n=3, >100 cells each). ** p < 0.01 by paired t-
test. 
(C) Schematic diagram of the modified semi-permeabilized cell assay. After SG induction with 
MG132, the plasma membrane is selectively permeabilized by digitonin and soluble proteins are 
washed out. To prevent nuclear import, nuclear pores are blocked by WGA before addition of 
MBP-FUS-EGFP ± TNPO1. After extensive washing, SGs are visualized by G3BP1 
immunostaining and recruitment of FUS into SGs is monitored by EGFP-fluorescence. 
(D) TNPO1 prevents recruitment of MBP-FUS-EGFP into SGs in semi-permeabilized cells. Nuclei 
were counterstained with DAPI (turquoise). 
(E) Quantification of the log-transformed mean fluorescence intensity of MBP-FUS-EGFP in SGs 
for 3 replicates SEM (≥10 cells, ≥32 SGs each). ***p<0.001 by Mann-Whitney test. 
 
Figure 3: C-terminal RGG/RG motifs crucially contribute to LLPS of FUS. 
(A) Schematic diagram of FUS domains and order/disorder prediction by the PONDR algorithm. 
(B) Upon addition of substoichiometric amounts of MAPT RNA, RGG3-PY forms liquid-like 
droplets at indicated protein concentrations. A KGG3-PY mutant does not form droplets at 60 µM. 
Bar, 10 µm. 
(C) Turbidity measurement to quantify phase separation of MBP-FUS-ΔRGG3-PY and MBP-FUS-
all-KGG in comparison to MBP-FUS-WT (7 µM) upon TEV cleavage. Values represent means  
SEM (n=3). ***p < 0.001 by one-way ANOVA with Dunnett´s multiple comparison test. 
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(D) Sedimentation assay to quantify phase separation of MBP-FUS-WT in comparison to MBP-
FUS-RGG3-PY and MBP-FUS-all-KGG by TEV-cleavage in the presence of 150 mM NaCl.  
(E) Quantification of the FUS levels in supernatant (S) and pellet (P) fractions as S/P ratio. Values 
represent mean  SEM (n=3). ** p<0.01 and ***p < 0.001 by one-way ANOVA with Bonferroni 
multiple comparison test. 
(F) Representative images of nitrocellulose (NC) and nylon membranes from filter-binding assays 
with MBP-FUS, TNPO1 and radioactively labeled ASH1 E3-51 RNA. Addition of 1 µM MBP-
FUS showed significant RNA binding, while increasing amounts of TNPO1 resulted in a decrease 
in signal intensity on the NC membrane but an increased signal on the nylon membrane. 
(G) ASH1 E3-51 RNA has no influence on phase separation of 5 µM MBP-FUS after TEV cleavage 
in a turbidity assay. Values represent means  SEM (n=3). 
See also Fig. S2. 
 
Figure 4: Arginine methylation of FUS reduces LLPS and SG association of FUS. 
(A) Droplet formation for unmethylated (unme) or methylated (me) FUS-EGFP at different protein 
concentrations following TEV cleavage of MBP-FUS-EGFP. Bar, 5 µm. 
(B) FRAP curves after half-bleach of 9 µM unmethylated (unme) or methylated (me) FUS-EGFP 
droplets (75 mM NaCl supplemented with 150 mg/ml Ficoll 400). Values represent means  SD 
(n=33). Representative pictures of indicated time-points are shown in (C). Boxes indicate bleached 
area. Bar, 2 µm. 
(D) Turbidity measurement over time to determine phase separation of 7 µM unmethylated (unme) 
or methylated (me) MBP-FUS in the presence of 75 mM NaCl upon TEV cleavage. Values 
represent means  SEM (n=3). 
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(E) Enhanced SG recruitment of unmethylated (unme) MBP-FUS-EGFP compared to methylated 
(me) MBP-FUS-EGFP in semi-permeabilized cells. Bar, 10 µm. 
(F) Quantification of the log-transformed mean fluorescence intensity of MBP-FUS-EGFP in SGs 
for 3 replicates  SEM ( ≥10 cells, ≥28 SGs each). ***p<0.001 by Mann-Whitney test. 
See also Fig. S3 and Table S2. 
 
Figure 5: The ALS-associated FUS-P525L mutation impairs the chaperone activity of 
TNPO1 
(A) Droplet formation after TEV cleavage of methylated 11 µM MBP-FUS-EGFP WT vs. P525L 
± TNPO1 after 0 and 8 h. Bar, 15 µm. 
(B) Percentage of image area covered by FUS-EGFP droplets. Values represent means  SEM 
(n=3). ** p<0.01 by paired t-test. 
(C) SG association of WT vs. P525L MBP-FUS-EGFP ± TNPO1 in the semi-permeabilized cell 
assay. Nuclei were counterstained with DAPI (turquoise). Bar, 20 µm. Note that image acquisition 
conditions differed from the experiment shown in Fig. 4E to visualize methylated FUS in SGs 
without TNPO1. 
(D) The mean reduction of SG association of FUS (-TNPO1 set to 100%) was calculated from 3 
independent experiments. (≥ 10 cells, ≥37 SGs each). *p<0.05 by paired t-test. 
(E) SG recruitment of cytosolically anchored (GCR2-tagRFP2-tagged) FUS-WT or -P525L in HeLa 
cells was monitored by co-immunostaining for tagRFP (green) and TIA1 (red). Nuclei were 
counterstained with DAPI (turquoise). Bar, 20 µm. 
(F) The percentage of cells showing SG-localized GCR2-tagRFP2-FUS. Values represent mean  
SEM (n=3 with n>100 cells each). 
See also Fig. S4 and Table S1. 
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SUPPLEMENTAL FIGURE TITLES AND LEGENDS 
 
Figure S1: TNPO1 inhibits and reverses phase separation of FUS in vitro, related to Figure 1:  
(A) Scheme of MBP-FUS-EGFP and MBP-FUS. Human FUS was N-terminally tagged with 
maltose binding protein (MBP), which keeps FUS soluble, and C-terminally with a His6-tag. In 
MBP-FUS-EGFP, FUS and the EGFP-His6 tag are separated by a 13 amino acid linker in order to 
preserve functionality of the PY-NLS. To initiate phase separation, the MBP- and His6-tags are 
cleaved off using TEV protease, which cleaves at the indicated sites (Tev). 
(B) Phase contrast microscopy demonstrates that TEV induces droplet formation when added to 
MBP-FUS harboring a Tev cleavage site, but does not cause phase separation of MBP-Precission-
FUS. Scale bar, 10 µm.  
(C) Preformed FUS-EGFP droplets (6 µM) were mixed with equimolar amounts of TNPO1. A 
highly concentrated TNPO1 stock (140 µM) stock in droplet buffer was used, to avoid changes in 
FUS-EGFP droplet concentration and buffer conditions. Droplets dissolve upon addition of 
TNPO1. Images were acquired by confocal fluorescence microscopy. Scale bar, 5 µm. 
(D) Pulldown (PD) testing for the direct interaction of MBP-FUS-EGFP, immobilized on amylose 
beads, with various proteins visualized by SyproRuby staining. Input and PD correspond to 5% or 
30%, respectively. Molecular weight markers (in kDa) are indicated on the left. 
 
Figure S2: Phase separation properties of RGG3-PY domain, related to Figure 3: 
(A) Amino acid sequence of RGG3-PY domain (RGG3 in light green, PY-NLS in light red) 
showing that it is highly enriched in RGG/RG motifs (bold). In the KGG3-PY mutant, all arginines 
in RGG motifs are replaced by lysine (highlighted in blue). 
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(B) and (C) Phase diagram of RGG3-PY at different protein concentrations as a function of 
temperature (B) or salt concentration (C), obtained by scoring for the presence of droplets (green 
circles) or absence of droplets (red diamonds).  
(D) Western blots with an antibody specific for FUS-RGG3 (14G1) demonstrating that signal is 
lost in mutant MBP-FUS proteins (FUS-RGG3-PY and FUS-all-KGG). Equal loading was 
demonstrated using an anti-FUS antibody binding N-terminally of the RGG3-domain (4H11). 
(E) NMR data demonstrating RNA-mediated phase separation of RGG3-PY. 1H-15N SOFAST-
HMQC spectrum of 15N-labeled RGG3-PY without (black) or with 0.2 stoichiometric equivalents 
of (UG)10 RNA (orange). Spectra were recorded with an interscan delay of 1.0 s, spectral widths 
of 16/32 ppm, centered at 4.7/115.0 ppm in 1H/15N, with 512 and 128 complex data points, 
respectively, and 8 scans per increment.  
(F) NMR data demonstrating that TNPO1 displaces RNA from RGG3-PY. Overlay of 1H NMR 
spectra of 15N-labeled RGG3-PY (black), in presence of 0.2 stoichiometric equivalents of RNA 
(orange), and with an additional stoichiometric equivalent of TNPO1 (light blue), respectively. The 
reference 1H NMR spectra of RNA at the same concentration of 20 µM is shown in grey (dotted 
line). Protein concentrations were 100 µM. Spectra were recorded with an interscan delay of 1.0 s, 
spectral widths of 20 ppm, centered at 4.7 ppm in 1H, with 512 complex data points and 256 scans.  
(G) Representative plot of relative signal intensities from filter binding assays shown in Fig. 3F. 
The relative intensity was plotted against the respective TNPO1 concentration. Curves were fitted 
using the exponential decay fitting algorithm (in Origin software). Table summarizes the amplitude 
and decay factor of three independent experiments. 
 
Figure S3: Comparison of phase separation properties of in vitro methylated versus 
unmethylated FUS, related to Figure 4: 
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(A) Scheme of in vitro methylation. Purified FUS proteins were in vitro methylated with 
recombinant PRMT1 as methylating enzyme and the methyl group donor S-adenosylmethionine 
(+SAM). A sample with PRMT1 and without SAM (-SAM) served as unmethylated control.  
(B) Methylation was confirmed by immunoblotting with antibodies specific for the FUS-RGG3 
domain containing unmethylated arginines (UMA-FUS, 14G1), monomethylated arginines 
(MMA-FUS, 15E11) and asymmetrically dimethylated arginines (ADMA-FUS, 9G6), 
respectively. Here, immunoblots shown for MBP-FUS-EGFP, immunoblotting with a GFP-
specific antibody demonstrates equal loading. Immunoblots for MBP-FUS and RGG3-PY 
demonstrated similar methylation efficiencies (data not shown). 
(C) Precipitation of unmethylated (unme) and methylated (me) FUS after cleavage of MBP-FUS 
by TEV protease. Equal volumes of supernatant (S) and pellet (P) fractions were analyzed by SDS-
PAGE/Sypro-Ruby stain. Molecular weight markers (in kDa) are indicated on the left. As indicated 
in the scheme in (A), PRMT1 (but not SAM) was present in both protein samples to ensure 
comparability. A quantification of the ratio P/S is shown in (D). Values represent means  SEM 
from three independent experiments.*p<0.05 by paired t-test. 
(E) Turbidity measurements to quantify phase separation of the unmethylated (unme) or methylated 
(me) RGG3-PY domain (30 µM) in presence of different amounts of in vitro transcribed MAPT 
RNA. Values represent means  SEM (n=3). **p < 0.01 and *p < 0.05 by paired t-test. 
(F) Representative images of nitrocellulose membranes from filter binding assay with 
unmethylated (unme) and methylated (me) RGG3-PY and radioactively labeled ASH1 E3-51 RNA.  
(G) Equilibrium dissociation constants (Kd) were determined using Hill fitting algorithm (n=6), 
also see Table S2. 
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Figure S4: Affinities of unmethylated and methylated RGG3-PY (WT and P525L) for 
TNPO1 and methylation status of MBP-FUS-EGFP (WT and P525L), related to Figure 5: 
(A) Titration of either 45 μM of RGG3-PY, meRGG3-PY or RGG3-PY (1M NaCl) into a solution 
containing 5 μM of TNPO1 (left, middle and right panel, respectively). The resulting Kds are 
indicated, also see Table S1. The reported errors correspond to the SD of the fit.  
(B) Titration of either 45 μM of RGG3-PY P525L, meRGG3-PY P525L or RGG3-PY P525L (1M 
NaCl) into a solution containing 4 μM of TNPO1 (left, middle and right panel, respectively). The 
resulting Kds are indicated, also see Table S1. The reported errors correspond to the SD of the fit.  
(C) Recombinant MBP-FUS-EGFP was in vitro methylated with recombinant PRMT1 and the 
methyl group donor S-adenosylmethionine (SAM +). A sample with PRMT1 and without SAM (–
) served as unmethylated control. Similar degree of methylation for MBP-FUS-EGFP WT and 
P525L was confirmed by immunoblotting with antibodies specific for the FUS-RGG3 domain 
containing unmethylated arginines (UMA-FUS, 14G1), monomethylated arginines (MMA-FUS, 
15E11) and asymmetrically dimethylated arginines (ADMA-FUS, 9G6), respectively. Samples 
from overnight (o.n.) incubation were used in experiments displayed in Fig. 5A-D.  
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STAR METHODS 
 
KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
FUS (4H11) Santa Cruz Cat# sc-47711 
UMA FUS (14G1) D. Dormann; 
(Suarez-Calvet 
et al., 2016) 
N/A 
MMA FUS (15E11) D. Dormann; 
(Suarez-Calvet 
et al., 2016) 
N/A 
ADMA FUS (9G6) D. Dormann; 
(Dormann et 
al., 2012) 
N/A 
G3BP1 Proteintech Cat# 13057-2-AP 
GFP (K3-184-2) A. Noegel; 
(Noegel et al., 
2004)  
N/A 
RFP Thermo Cat# R10367 
TIA-1 Santa Cruz Cat# sc-48371 
Alexa 555 Donkey anti-rabbit Thermo Cat# A-31572 
Alexa 647 Donkey anti-rabbit Thermo Cat# A-31573 
Alexa 647 Donkey anti-goat Thermo Cat# A-21447 
IRDye® 680RD Donkey anti-Mouse IgG LI-COR P/N 926-68072 
IRDye® 680RD Goat anti-Rat IgG LI-COR P/N 926-68076 
IRDye® 800CW Donkey anti-Mouse IgG LI-COR P/N 926-32212 
Chemicals, Peptides, and Recombinant Proteins 
AcTEV Protease Thermo Cat# 12575015 
GST-Precission M. Geyer N/A 
Benzonase® Nuclease Sigma Cat# E1014 
Importin 5 D. Görlich; 
(Jakel et al, 
2002) 
N/A 
S-(5′-Adenosyl)-L-methionine p-toluenesulfonate Sigma Cat# A2408 
TEM grids, carbon film coated, approx. 5-6 nm, 400 
Mesh, Cu 
Science 
Services 
Cat# ECF400-Cu-25 
4% Uranyl Acetate Solution Science 
Services 
Cat# E22400-4 
[γ32P]ATP Hartmann 
Analytic 
Cat# SRP-401 
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DMEM, high glucose, GutaMAX™ supplement Thermo Cat# 61965059 
Fetal Bovine Serum, qualified, heat inactivated, 
E.U.-approved, South America Origin 
Thermo Cat# 10500064 
Fetal Bovine Serum, dialyzed, US origin  Thermo Cat# 26400044 
Gentamicin (10 mg/mL) Thermo Cat# 15710049 
TurboFect™ Transfection Reagent Thermo Cat# R0534 
Aprotinin Roth Cat# A162 
Leupeptin hemisulfate Roth Cat# CN33 
Pepstatin A Roth Cat# 2936 
Lectin from Triticum vulgaris (Wheat germ 
agglutinin, WGA) 
Sigma Cat# L9640 
Digitonin Calbiochem Cat# 300410 
ProLong™ Diamond Antifade Mountant Thermo Cat# P36965 
DAPI Sigma Cat# D9542 
Poly-L-Lysine Sigma Cat# P9155 
Sypro-Ruby Protein Gel Stain Sigma Cat# S4942 
Bacterial and Virus Strains  
BL21-Codon Plus (DE3)-RIPL Agilent 
Technologies 
Cat# 230280 
BL21-DE3-Rosetta-LysS D. Niessing N/A 
BL21-DE3 Rosetta C. Haass N/A 
BL21-DE3 Agilent 
Technologies 
Cat# 200131 
Experimental Models: Cell Lines 
HeLa P4 R. 
Kehlenbach; 
(Charneau et 
al., 1994)  
N/A 
HeLa Kyoto I. Poser and A. 
Hyman 
RRID: 
CVCL_1922 
Recombinant DNA 
pMal-Tev-Flag-FUS-Tev-His6 This paper N/A 
pMal-Tev-FUS (WT)-EGFP-Tev-His6 This paper N/A 
pMal-Tev-FUS (P525L)-EGFP-Tev-His6 This paper N/A 
pMal-C2-Tev-Flag-FUS-ΔRGG3-PY-Tev-His6 This paper N/A 
pMal-C2-Tev-Flag-FUS-all-KGG-Tev-His6 This paper N/A 
pEX-A2-linker-EGFP-His6 This paper, 
IDT 
N/A 
petM11-His6-ZZ-Tev-FUS-RGG3-PY (WT and 
P525L) 
D. Dormann; 
(Dormann et 
al., 2012)  
N/A 
petM11-His6-ZZ-Tev-FUS-KGG3-PY This paper N/A 
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petM11-His6-ZZ-Tev-TNPO1 T. Madl; 
(Suarez-Calvet 
et. al., 2016) 
N/A 
pET28b-PRMT1 E. Wahle; 
(Zhang and 
Cheng, 2003) 
N/A 
His6-TEV in a pET-24d(+) vector A. Geerlof N/A 
pEGFP-bimax D. Dormann; 
(Dormann et 
al., 2010) 
N/A 
pRSV-EGFP-M9M This paper  N/A 
GCR2-tagRFP2-FUS WT This paper  N/A 
GCR2-tagRFP2-FUS P525L This paper  N/A 
pGM3 mTauI9-28560 D. Edbauer, 
(Orozco et al., 
2012) 
N/A 
Oligonucleotides 
Primers for PCR, see Table S3 This paper N/A 
Oligonucleotides, see Table S3 This paper N/A 
Software and Algorithms 
ImageJ (Fiji) NIH, 
(Schindelin et 
al., 2012) 
https://imagej.nih.go
v/ij/download.html 
Image Studio Lite Li-COR https://www.licor.co
m/bio/products/softw
are/image_studio_lit
e/download.html 
Zen2 blue edition (lite) Zeiss https://www.zeiss.de
/mikroskopie/downlo
ads/zen.html 
LAS X Leica http://www.leica-
microsystems.com/p
roducts/microscope-
software/software-
for-life-science-
research/las-x-
powerful-and-
flexible/#downloads 
GraphPad Prism5 GraphPad 
Software, Ink 
N/A 
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PONDR® VL-XT Molecular 
Kinetics, Inc., 
Washington 
State 
University; 
WSU 
Research 
Foundation 
http://www.pondr.co
m/ 
TEM Center Software JEOL N/A 
Sight X Viewer Software JEOL N/A 
Origin OriginLab http://www.originlab.
de/ 
TopSpinTM 3.1 Bruker https://www.bruker.c
om/products/mr/nmr/
nmr-software/ 
software.html 
 
CONTACT FOR REAGENT AND RESOURCE SHARING 
Further information and requests for reagents may be directed to, and will be fulfilled by the lead 
contact D. Dormann (dorothee.dormann@med.uni-muenchen.de) 
 
EXPERMENTAL MODEL AND SUBJECT DETAILS 
Cell culture and transfection 
HeLa Kyoto cells for transient transfection experiments and HeLa-P4 cells (Charneau et al., 1994) 
for semi-permeabilized cell assays were grown in DMEM high glucose GlutaMAX (Invitrogen) 
supplemented with 10% dialyzed FBS, or 10% standard FBS and 10 µg/ml gentamicin, 
respectively. Cells were maintained in a humidified incubator at 37°C with 5% CO2. Transient 
transfections were performed using Turbofect following manual instructions. Note, that for 
transfection of GCR2-tagRFP2-FUS constructs low DNA amounts (20% GCR2-tagRFP2-FUS, 80% 
plasmid coding for EGFP/EGFP-bimax/EGFP-M9M) to minimize aggregation of FUS due to 
overexpression.  
 
Bacterial Growth 
All bacterial cultures were grown at 37°C under constant shaking (140-160 rpm) in standard 
lysogeny broth (LB) medium. Before induction of protein expression, cultures were cooled down 
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to the temperature indicated for the respective protein in the section “Recombinant protein 
expression and purification”. 
 
METHOD DETAILS 
Generation of cDNA constructs 
pMal-Tev-Flag-FUS-Tev-His6 was created by cloning PCR amplified N-terminal Flag-tagged and 
C-terminal Tev-His6 tagged FUS cDNA into the SalI-HindIII sites of pMal-Tev using primers 
SalI_flag_F and HindIII_His6-Tev-FUS_R. pMal-Tev was created by cloning annealed double 
stranded oligonucleotides Tev_F and Tev_R (coding for the Tev cleavage site) into the EcoRI-SalI 
sites of pMal-c. 
To generate pMal-Tev-FUS-EGFP-Tev-His6, FUS cDNA was PCR amplified from pMal-Tev-Flag-
FUS-Tev-His6 using primers SalI_FUS_F and BamHI_FUS_R, thus introducing a C-terminal 
BamHI restriction site. EGFP-His6 with low-complexity linker was cut from synthetic pEX-A2-linker-
EGFP-His6 (IDT) using BamHI and HindIII sites. In a triple ligation, FUS and EGFP-His6 fragments 
were cloned into the pMal-Tev backbone derived from pMal-Tev-flag-FUS-Tev-His6. 
pMal-Tev-FUS (P525L)-EGFP-Tev-His6 was generated by site directed mutagenesis of pMal-Tev-
FUS-EGFP-Tev-His6 using primers FUS wt-EGFP mut P525L_F and FUS wt-EGFP mut 
P525L_R. 
To generate pMal-C2-Tev, the C-terminus of MBP including parts of the MCS was PCR-amplified 
(MBP_NcoI_F; MBPLinker_Tev_EcoRI) introducing a Tev-cleavage site in the reverse primer and 
replacing the factor Xa cleavage site in the original pMal-C2 (NEB) vector. 
pMal-C2-Tev-Flag-FUS ΔRGG3-PY-Tev-His6 was generated by cloning PCR amplified N-terminal 
Flag-tagged and C-terminal Tev-His6 tagged FUS cDNA encoding amino acids 1-453 into the SalI-
HindIII sites of pMal-C2-Tev using primers SalI_flag_F and HindIII_FUS453X-Tev-His6_R. 
To generate pMal-C2-Tev-Flag-FUS-all-KGG-Tev-His6, FUS cDNA was PCR amplified from a 
synthetic plasmid with all RGGs mutated to KGGs using primers XhoI_FUS_F and HindIII_Tev-
His6- -FUS_R and cloned into the pMal-C2-TEV backbone derived from pMal-C2-Tev-Flag-FUS 
ΔRGG3-PY-Tev-His6. 
petM11-His6-ZZ-Tev-FUS-KGG3-PY was generated by cloning FUS cDNA encoding amino acids 
454-526 from a synthetic plasmid with all RGGs mutated to KGGs using primers FUS 454_NcoI_F 
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and BamHI_FUS_R and cloned into the petM11-His6-ZZ backbone derived from petM11-His6-ZZ-
Tev-FUS-RGG3-PY. 
To generate pETM11-His6-ZZ-Tev-TNPO1, the human TNPO1 cDNA sequence was codon 
optimized for protein production in bacterial cells and flanked by NcoI and BamHI restriction sites 
(Genscript). The coding region was cloned into a modified pETM11 bacterial expression vector, 
which includes an N-terminal His6, protein A (ZZ) tag and a TEV protease cleavage site. 
To generate GCR2-tagRFP2-FUS, the EGFP2-sequence in a modified EGFP-C1 vector containing 
a GCR2-EGFP2-cassette (Hutten et al., 2008) was replaced sequentially with a two cDNAs coding 
for tagRFP (primer: TagRFP_AgeI/TagRFP_EcoRV and TagRFP_Spe/ TagRFP_AgeI_R). FUS 
wt or P525L was inserted via EcoRV/BamHI sites replacing the NLS sequence (primer: 
FUS_EcoRV_f with either FUS_BamHI_R or FusP525L_BamHIr). 
The pRSV-EGFP-M9M construct was generated by replacing the CMV-promoter in pEGFP-M9M 
(Dormann et al., 2010) by a RSV promoter sequence (gift from M. Kiebler) via AseI/NheI. 
 
Recombinant protein expression and purification 
For expression of recombinant MBP-FUS-His6 (WT, ΔRGG3-PY, and all-KGG) and MBP-FUS-
EGFP-His6 (WT and P525L), the respective bacterial expression vectors were transformed into E. 
coli BL21-DE3-RIPL and BL21-DE3-Rosetta-LysS, respectively, and grown in standard lysogeny 
broth (LB) medium. At an OD (600 nm) of ~ 0.8, cells were induced with 0.1 mM IPTG for 22 h at 
12°C. Cells were lysed in resuspension buffer (50 mM Na2HPO4/NaH2PO4, pH 8.0, 300 mM NaCl, 
10 µM ZnCl2, 40 mM imidazole, 4 mM βME) + 10 % glycerol and tandem-affinity purification using 
HisTrap FF columns (GE Healthcare) and amylose resin (NEB) was performed. The protein was 
washed with resuspension buffer and eluted in resuspension buffer including 250 mM imidazole 
and 20 mM maltose, respectively.  
For expression of recombinant His6-Tev, E. coli BL21-Ros-LysS were transformed with the 
expression plasmid and grown in standard LB medium. Induction of expression was induced at 
OD (600 nm) of ~0.6 with 1mM IPTG overnight at 20°C. Cells were lysed in lysis buffer (50 mM 
Tris pH8, 200 mM NaCl, 20 mM imidazole, 10% glycerol, 4 mM -mercaptoethanol, 1 µg/ml each 
of aprotinin, leupeptin and pepstatin) by addition of lysozyme and sonification. The lysate was 
incubated in the presence of RNase A (0.1mg/ml final concentration) for 30min at RT. His-Tev 
was purified using Ni-NTA beads and washed using lysis buffer containing 1M NaCl. His6-Tev was 
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eluted in lysis buffer (pH 8.5) containing 800mM imidazole and dialyzed against storage buffer 
(20mM Tris pH 7.4; 150mM NaCl; 20% glyercole, 2mM DTT). 
For expression of the RGG3-PY domain, pETM11-His6-ZZ-FUS-RGG3-PY (WT and KGG3-PY) 
were transformed into E. coli BL21-DE3 Rosetta and were expressed at 37 °C for 4 h. Cells in 
resuspension buffer were lysed by boiling for 20 min at 90 °C, as boiling lysis allows removal of 
folded proteins from cell lysates, while intrinsically disordered proteins stay soluble (Livernois et 
al., 2009). His6-ZZ tagged proteins were bound to nickel-nitrilotiacetic (Ni-NTA) resin (Qiagen), 
incubated with Benzonase® Nuclease (Sigma) overnight at 4°C in Benzonase buffer (50 mM 
Na2HPO4/NaH2PO4, pH 8.0, 50 mM NaCl, 2 mM MgCl2) and subjected to high salt washes with 
resuspension buffer containing 2 M NaCl and then eluted in resuspension buffer + 250 mM 
imidazole. In order to proteolytically remove the His6-ZZ tag, His6-TEV protease (2.5 mg) was 
added to eluted His6-ZZ-RGG3-PY proteins and dialyzed against TEV cleavage buffer (20 mM 
Na2HPO4/NaH2PO4, pH 8.1, 150 mM NaCl, 5% glycerol, 4 mM βME) overnight at 4 °C. His6-TEV 
and His6-ZZ tag were removed by incubation with Ni-NTA resin (Qiagen), while untagged RGG3-
PY remains in the supernatant. 
For ITC or NMR experiments, pETM11-His6-ZZ-FUS-RGG3-PY (WT or P525L) were transformed 
into E. coli BL21-DE3 Star strain. For the unlabeled protein, cells were grown for 1 day at 37°C in 
standard lysogeny broth (LB) medium. At an OD (600 nm) of ~ 0.8, cells were induced with 0.1 
mM IPTG for 22 h at 12°C. To obtain 15N labeled protein, cells were grown for 1 day at 37°C in 
minimal medium (100 mM KH2PO4, 50 mM K2HPO4, 60 mM Na2HPO4, 14 mM K2SO4, 5 mM MgCl2; 
pH 7.2 adjusted with HCl and NaOH with 0.1 dilution of trace element solution (41 mM CaCl2, 22 
mM FeSO4, 6 mM MnCl2, 3 mM CoCl2, 1 mM ZnSO4, 0.1 mM CuCl2, 0.2 mM (NH4)6Mo7O24, 17 
mM EDTA) supplemented with 6 g of 12C6H12O6 and 1 g of 15NH4Cl (Sigma). At an OD (600 nm) 
of ~ 0.8, cells were induced with 0.5 mM IPTG for 16 h at 20°C. Cell pellets were harvested and 
sonicated in denaturing buffer containing 50mM Tris-HCl pH 7.5, 150 mM NaCl, 20 mM imidazole, 
2 mM tris(2-carboxyethyl)phosphine (TCEP), 20% glycerol and 6M urea. His6-ZZ proteins were 
purified using Ni-NTA agarose (Qiagen) and eluted in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 200 
mM imidazole, 2 mM TCEP and subjected to TEV treatment. Untagged proteins were then isolated 
performing a second affinity purification using Ni-NTA beads. A final exclusion chromatography 
purification step was performed in the buffer of interest on a gel filtration column (Superdex 
peptide, GE Healthcare). 
For expression of recombinant His6-TNPO1, the bacterial expression vector pETM11-His6-ZZ-
Tev-TNPO1 was transformed into E. coli BL21-DE3 Star cells. Expression cultures of 1 l volume 
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were grown for 2 days in minimal medium (100 mM KH2PO4, 50 mM K2HPO4, 60 mM Na2HPO4, 
14 mM K2SO4, 5 mM MgCl2; pH 7.2 adjusted with HCl and NaOH with 0.1 dilution of trace element 
solution (41 mM CaCl2, 22 mM FeSO4, 6 mM MnCl2, 3 mM CoCl2, 1 mM ZnSO4, 0.1 mM CuCl2, 
0.2 mM (NH4)6Mo7O24, 17 mM EDTA) supplemented with 6 g of glucose and 3 g of NH4Cl. Cells 
were diluted to an OD (600 nm) of 0.8 and induced with 0.5 mM IPTG followed by protein 
expression for 4 h at room temperature. His6-TNPO1 was purified using Ni-NTA agarose (Qiagen) 
and eluted in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 200 mM imidazole, 2 mM TCEP. A final size 
exclusion chromatography step was performed in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 20 mM 
imidazole, 2 mM TCEP, 20% glycerol on a gel filtration column (Hiload 16/600 Superdex 200 pg, 
GE Healthcare). Note, that for ITC/NMR experiments, the His-tag was removed by TEV cleavage.  
For expression of recombinant His6-PRMT1, the pET28b-PRMT1 vector was transformed into E. 
coli BL21-DE3 Star and 1 l expression culture was grown in LB medium. Cells were induced at an 
OD (600 nm) of 0.8 with 0.5 mM IPTG followed by protein expression for 16 h at 20°C. Cell pellets 
were harvested and sonicated in 50mM Tris-HCl pH 7.5, 150 mM NaCl, 20 mM imidazole, 2 mM 
TCEP, 20% glycerol. His6-PRMT1 was purified using 5 mL HisTrap HP column (GE Healthcare), 
eluted in 50 mM Tris-HCl pH 7.5, 1 M NaCl, 500 mM imidazole, 2 mM TCEP and further purified 
by size exclusion chromatography as described for TNPO1 above. 
Protein concentrations were determined from their absorbance at 280 nm using ε predicted by the 
ProtParam tool. For all assay that involved addition of RNA, 260/280 nm ratios of purified proteins 
were between 0.6 and 0.8. 
 
In vitro methylation 
FUS proteins and PRMT1 were dialyzed against in vitro methylation (IVM) buffer containing 20 
mM Na2HPO4/NaH2PO4, pH 8.1, 150 mM NaCl, 5% glycerol, 1 mM EDTA, 1 mM DTT or 50 mM 
Na2HPO4/NaH2PO4, pH 8.0, 150 mM NaCl, 2 mM TCEP for ITC and NMR experiments. FUS 
proteins were in vitro methylated by incubating with PRMT1 and 1 mM S-adenosyl-L-methionine 
(SAM) overnight at room temperature. PRMT1 was used at a molar ratio of 2:1 for MBP-FUS, 
1.5:1 for RGG3-PY or KGG3-PY (used in droplet and turbidity assays) and 0.2:1 for RGG-PY 
proteins used in ITC or NMR experiments. For RGG3-PY proteins, PRMT1 was removed by 
boiling the samples for 10 min at 90°C. 
 
In vitro transcription 
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MAPT RNA and ASH1 E3-51 RNA were produced by in vitro transcription (MEGAshortscript Kit; 
Ambion) using linearized pGM3 mTauI9-28560 or primers P45 and P132, respectively. 
For filter binding assays the ASH1 RNA was radioactively labeled using [γ32P]ATP and T4 
polynucleotide kinase (NEB). The RNA was separated from free nucleotides using NucAway spin 
columns (Ambion). 
 
In vitro phase separation assays 
Droplet assay for microscopy 
Purified RGG3-PY or KGG3-PY and His6-TNPO1 were buffer exchanged to droplet buffer (20 mM 
Na2HPO4/NaH2PO4, pH 7.5, 75 mM NaCl, 2.5% glycerol, 1 mM DTT) and concentrated in 
Amicon® Ultra Centrifugal Filter Devices (Millipore). For droplet formation of C-terminal RGG3-PY 
proteins, proteins were diluted to indicated concentrations and supplemented with in vitro 
transcribed MAPT RNA (a known FUS target RNA, Orozco et al., 2012) at a molar ratio of 1:50, 
as this ratio was found to maximally promote phase separation. His6-TNPO1, His6-Importin 5, 
FUS RGG3, or His6-PRMT1, respectively, were used at equimolar concentrations to FUS. 
Purified full-length MBP-FUS-EGFP (WT or P525L) or MBP-FUS were diluted in droplet buffer 
including 150 mM NaCl, if not otherwise stated in the figure legend. Full-length FUS was only 
supplemented with RNA when explicitly mentioned in the figure legend (Fig. 3G). Phase 
separation was induced by addition of acTEV protease (Invitrogen) at 25°C. With the exception of 
Figure 4A, where widefield fluorescence microscopy was applied, imaging of EGFP-tagged FUS 
was performed by confocal microscopy. Non-fluorescent FUS-droplets were imaged by phase 
contrast microscopy.  
Note that phase separation properties, i.e. critical concentration for droplet formation, differ slightly 
between different protein preparations. 
 
In vitro aging assay 
To induce aging of FUS-EGFP droplets, TEV-cleaved samples were subjected to 700 rpm on an 
orbital shaker at RT for 8h and additionally mixed by pipetting up and down every hour. Samples 
were imaged in 384-well plates by confocal microscopy. 
 
Turbidity assay 
Phase separation of RGG3-PY and MBP-FUS in the absence or presence of equimolar amounts 
of His6-TNPO1, His6-Importin 5, FUS RGG3, or His6-PRMT1, respectively, was induced as 
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described above for the droplet assay. Turbidity measurements were conducted at 600 nm in 384-
well plates with 20 µl samples using a BioTek Power Wave HT plate reader. All experiments were 
performed in triplicate. 
 
Sedimentation assay 
For sedimentation analysis of full-length FUS, the MBP-tag of 1 µM purified MBP-Flag-FUS protein 
in the absence or presence of equimolar amounts of His6-TNPO1, His6-Importin 5, FUS RGG3, 
or His6-PRMT1, respectively, was cleaved using 0.1 mg/ml His6-TEV in 50 µl reaction buffer (50 
mM Tris pH 8, 0.5 mM EDTA, 1 mM DTT) for 60 min at 30 °C, followed by centrifugation at room 
temperature for 15 min at 16,000-20,000 g. Equal volumes of supernatant and pellet fraction were 
analyzed by SDS-PAGE and either SyproRuby stain (Fig.3D, S3C) or Western Blot with a FUS-
specific antibody (4H11) (Fig 1D).  
 
Semi-permeabilized cell assay 
HeLa P4 cells were grown on poly-L-lysine coated 12 mm coverslips, permeabilized with 0.003-
0.005% digitonin in KPB (20 mM potassium phosphate pH 7.4, 250 mM sucrose, 5 mM Mg(OAc)2, 
200 mM KOAc, 1 mM EGTA, 2 mM DTT and 1µg/ml each aprotinin, pepstatin and leupeptin). After 
several washes to remove soluble proteins (4 x 4 min in KPB on ice), nuclear pores were blocked 
by 15 min incubation with 200 µg/ml wheat germ agglutinin (WGA) on ice. Cells were then 
incubated for 30 minutes at room temperature with 125 nM MBP-FUS-EGFP in the absence or 
presence of 1.25 µM His6-TNPO1 in KPB. Note that a 10-fold excess of TNPO1 was required for 
efficient shielding of FUS, possibly due to other RBPs present in SGs that bind to TNPO1. 
Subsequently, cells were washed (3 x 5 min in KPB on ice) to remove unbound MBP-FUS-EGFP. 
SGs were visualized by immunostaining of G3BP1. Note that G3BP1 immunostaining also served 
as a control for proper permeabilization, as non/poorly-permeabilized cells still show diffuse 
cytoplasmic G3BP1 staining. Cells were imaged by confocal microscopy using identical settings 
for reactions within the same experiment. 
 
Filter binding assay 
The indicated protein concentrations were incubated with 0.5 nM of in vitro transcribed, 
radiolabeled ASH1 E3-51 RNA in a total volume of 80 µL in filter-binding buffer (20 mM Na 
phosphate, 50 mM NaCl, 2 mM DTT, pH 7.5). Samples were applied to nitrocellulose and nylon 
membranes, using a Dot Blot Aparatus (BioRad), and washed twice with 80 µl filter-binding buffer. 
Membranes were air-dried and analyzed by phosphorimaging using a Fujifilm FLA-3000 scanner.  
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Immunostaining or Immunocytochemistry 
Cells grown on coverslips were either fixed ~20 h after transfection or after the semi-permeabilized 
cell assay in 3.7% formaldehyde/PBS buffer for 7-10 min at RT and permeabilized in 0.5% TX-
100/ PBS for 5 min at room temperature. Cells were blocked for 10 min in blocking buffer (1% 
donkey serum in PBS/ 0.1% Tween-20) and incubated with primary antibodies in blocking buffer 
for 1-2h at RT or overnight at 4°C. Secondary antibodies were diluted in blocking buffer and 
incubated for 1h at room temperature. Washing steps after antibody incubation were performed 
with PBS/0.1% Tween-20. DNA was stained with DAPI at 0.5 µg/ml in PBS and cells mounted in 
ProLong™ Diamond Antifade. Imaging was performed by confocal microscopy. 
 
Microscopy 
Phase contrast and wide-field fluorescence microscopy 
For imaging of FUS droplets, samples were placed in sealed sample chambers formed by a hole 
punched into a double-sided sticky tape, taped onto a glass slide and sealed with a coverslip.  
For imaging of RGG3-PY and FUS droplets by phase contrast microscopy, a 63x/1.40 Oil/Ph3 
objective was used; FUS-EGFP droplets in Figure 4A were imaged by fluorescence microscopy 
using a 63x/1.40 Oil objective, both on an Axio Oberver.Z1 wide-field fluorescence microscope 
and an AxioCam 506 (Zeiss, Oberkochen, Germany).  
 
Confocal microscopy 
Confocal microscopy was performed at the Bioimaging core facility of the Biomedical Center with 
an inverted Leica SP8 microscope, equipped with lasers for 405, 488, 552 and 638 nm excitation. 
Images were acquired using two-fold frame averaging with a 63x1.4 oil objective, and an image 
pixel size of 71 nm or 59 nm for droplets and cells, respectively. The following fluorescence 
settings were used for detection: DAPI: 419-442 nm, GFP: 498-533 nm, RFP/Alexa 555: 562-598 
nm, Alexa 647: 650-700 nm. If applicable, recording was performed sequentially to avoid bleed-
through using a conventional photomultiplier tube.  
 
FRAP  
In contrast to all other experiments in this study, droplet buffer including 75 mM NaCl was 
supplemented with 150 mg/ml Ficoll 400 in order to obtain droplets of similar size and shape for 
FRAP experiments. Experiments were performed on an inverted microscope (Axio Observer.Z1; 
Carl Zeiss, Oberkochen, Germany) equipped with a confocal spinning disk unit (CSU-X1; 
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Yokogawa, Tokyo, Japan) and a Zeiss 100x/1.46 Oil Ph3 oil immersion lens. Images were 
acquired in the streaming mode using the 488 nm SD laser line and fixed exposure times of 50 
ms and an EM-CCD camera (EvolveDelta; Photomoetrics) at bin 1x1. For localized 
photobleaching (“half-bleach”), a laser scanning device (UGA-42 Geo; Rapp OptoElectronic, 
Hamburg, Germany) was used. The “Geo” module allowed for simultaneous laser illumination 
within hardware-defined shapes of different sizes. Here, a square-like shape with an illumination 
size of ~4 µm in the sample was selected. For each experiment, half of the observed structure 
was bleached to approximately 50% of the initial intensity using a 473 nm diode laser (DL-473/75; 
Rapp OptoElectronic, Hamburg, Germany). 
 
Transmission electron microscopy (TEM) 
Carbon coated copper grids (carbon film coated 400 mesh copper grids, Science Services) were 
glow discharged for 2 min in a Harrick plasma cleaner (PDC-32G-2) to facilitate protein adsorption. 
MBP-FUS (7 µM) -/+ TNPO1 (7 µM) was incubated with TEV protease for 90 min and 
subsequently diluted to 2 µM and deposited on the grid surface. The grid was washed twice in a 
drop of double distilled water, blotted shortly using filter paper. Fixing the grid by inverse forceps, 
3 µl of 1% uranyl acetate were added to the grid for 30 s. After blotting, the grid was air dried for 
at least 30 min. Mosaics of three by three images were obtained at a magnification of 60.000 using 
a JEOL JEM 1400-plus electron microscope at 120 kV (TEM Center software, JEOL). The Sight 
X Viewer (JEOL) and ImageJ (NIH) Software packages were applied for mosaic stitching. 
 
NMR 
All proteins / RNA samples were prepared in 20 mM Na2HPO4/NaH2PO4 pH 7.5, 75 mM NaCl, 
2.5% glycerol, 1 mM DTT and 10% 2H2O added for the lock signal. NMR experiments were 
performed at 25°C on Bruker 700 MHz spectrometer. Spectra were processed using Topspin 3.5 
and Mnova 11.  
 
Isothermal Calorimetry 
All protein samples were prepared either in 50 mM Tris-HCl (pH 7.5), 150 mM NaCl and 2 mM 
tris(2-carboxyethyl)phosphine (TCEP) or in 50 mM Tris-HCl (pH 7.5), 1 M NaCl and 2 mM TCEP. 
ITC measurements were carried out on a MicroCal VP-ITC instrument (Microcal, Northhampton, 
USA) with 36 rounds of 8 μl injections at 25 °C.  Integration of peaks corresponding to each 
injection, subtraction of the contribution of protein dilution and correction for the baseline were 
performed using the Origin-based 7.0 software provided by the manufacturer. Curve fitting was 
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done with a standard one-site model and gives the equilibrium binding constant (Ka), and enthalpy 
of the complex formation (ΔH). 
 
 
QUANTIFICATION AND ANALYSIS 
Statistics 
Statistical analyses were performed in GraphPad Prism 5. For 2-grouped analyses, for which 
control and treatment groups were handled in parallel, a paired t-test was applied. If 
measurements were not normally distributed, a non-parametric test (Mann-Whitney) was chosen. 
1-way ANOVAs were applied to multi-group comparisons. Here, a Bonferroni post-test was 
applied when significance between all groups was analyzed, whereas a Dunnett’s multiple 
comparison test was applied when the significance of all values to a single condition was analyzed. 
 
Image analysis 
Confocal images were acquired using LAS X (Leica), all other images were acquired in ZEN2 
(Zeiss). For illustration of FRAP of FUS-EGFP droplets, images were displayed as heat map and 
processed using the interpolation function in ZEN2. All other images were processed using Image 
J/Fiji software applying linear enhancement for brightness and contrast. For quantitative 
measurements, equal exposure times and processing conditions for respective channels were 
applied to all samples within one experiment. For better visibility, in some figures the individual 
channels were displayed in artificial colors as indicated in the figure legends. 
 
Droplet quantification 
Confocal images were imported in the public-domain software Image J/Fiji (Schindelin et al., 
2012)and a Median filter with radius 2 was applied. Huang auto threshold method providing best 
coverage of the droplet area was applied. Structures touching the edge of the image section and/or 
smaller than 0.5 µm2 were excluded from particle analysis. If required, a watershed analysis was 
performed. 
 
Quantification of MBP-FUS-EGFP in SGs 
For quantitative measurements, equal exposure times and processing conditions for respective 
channels were applied to all samples within one experiment. In Image J/Fiji, ROIs corresponding 
to SGs were identified using the wand tool by G3BP1 staining and mean fluorescence intensity in 
the EGFP channel was determined. For each condition, at least 10 cells and at least 28 SGs were 
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analyzed. For display of fluorescence intensity of FUS in SGs, measured fluorescence values 
were log transformed to achieve a more balanced spread. Statistical analyses were performed in 
GraphPad Prism 5.  
 
Quantification of filter-binding assays 
Membranes from filter-binding assays were scanned by a FujiFilm FLA-3000 imaging machine. 
Quantification of signal intensities was carried out using the Dot Blot Analyzer macro within the 
Image J software. For binding experiments, the raw intensities of the individual dots on the 
nitrocellulose membrane were normalized against the raw intensity measured for the highest FUS 
concentration. For outcompetition experiments, a ratio of the intensity on the nitrocellulose 
membrane versus the intensity on nitrocellulose and nylon membrane was determined. The 
obtained relative intensities were plotted against the protein concentration and fitted using the 
non-linear curve-fitting tool in Origin software.  
 
FRAP analysis 
Intensities of bleached areas were corrected both for bleaching due to imaging over time and 
background noise. The corresponding calculations were performed with the FIJI/ImageJ macro 
“TimeSeries Analyzer” by calculating the fluorescence intensity over time (I(t)) as follows:  
 
I(t) = [ROI1(t)–ROI3(t)]/[ROI2(t)–ROI3(t)] 
 
with ROI1 giving the averaged gray values of the bleached area, and ROI2 corresponds to the 
averaged gray values of the total droplet. ROI3 corresponded to the averaged background values. 
Obtained values were further normalized to the initial fluorescence by dividing I(t) by the mean 
gray value of the initial 4 time steps before bleaching <I(1-4)>. 
 
Densitometry measurements  
To determine the solubility of FUS by sedimentation analysis of TEV-cleaved MBP-FUS, 
densitometry measurements of band intensities after Sypro-Ruby staining or FUS immunoblotting 
of supernatant and pellet fractions, respectively, were performed using standard plugins in the 
Image J software.  
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Table S1 (related to Fig. 5): Thermodynamic parameters of ITC titrations 
Cell                 Syringe                               Kd (nM)          ΔH (kcal*mol-1)            ΔS (cal*mol1*K) 
TNPO1                RGG3-PY                                  3 ± 1                   -26.5 ± 0.1                  -49.7                          
TNPO1                meRGG3-PY                             126 ± 20             -25.3 ± 0.1                  -48.6 
TNPO1                RGG3-PY (1M NaCl)                398 ± 31            -18.9 ± 0.4                  -34.3 
TNPO1                RGG3-PY P525L                        27 ± 2               -17.6 ± 0.1                  -24.5 
TNPO1                meRGG3-PY P525L                   356 ± 27           -17.4 ± 0.2                  -28.6               
TNPO1                RGG3-PY P525L (1M NaCl)         no detectable binding 
The reported errors correspond to the SD of the fit. 
All the stoichiometry associated to the complex formation was equal to 1. 
 
 
 
Table S2 (related to Fig. 4): Kinetic parameters of filter binding assays (RGG3-PY with 
RNA) 
   unmeRGG3-PY  meRGG3-PY 
Kd (µM) 1.01 +/- 0.05 1.04 +/- 0.14 
Hill coefficient 3.55 +/- 0.78 3.62 +/- 0.6 
N   6    6 
The reported errors correspond to the mean ± SD. 
 
 
 
 
Table S3 (related to Figure STAR Methods): Sequences of PCR primers and 
oligonucleotides 
Name Source Sequence 
PCR primer 
SalI_flag_F Microsynth AG AAAAGTCGACATGGAC
TACAAGGACGACGAT
G 
HindIII_Tev-His6- -FUS_R Microsynth AG GTGCCAAGCTTTCAGT
GATGATGATGATGATG
GCTTTGGAAATACAGA
TTTTCATACGGCCTCT
CCCTGCGATCC 
Tev_F Microsynth AG AATTCGGCGGCGAAA
ATCTGTATTTCCAAAG
CG 
Tev_R Microsynth AG TCGACGCTTTGGAAAT
ACAGATTTTCGCCGCC
G 
SalI_FUS_F Eurofins AAAAGTCGACATGGCCTCAAACGATTATA 
BamHI_FUS_R Eurofins TTTTGGATCCATACGGCCTCTCCCT 
FUS wt-EGFP mut P525L_F 
Eurofins AGGGAGAGGCTGTAT
GGATCCGGCGCACCT
GGCTCA 
FUS wt-EGFP mut P525L_R 
Eurofins TGAGCCAGGTGCGCC
GGATCCATACAGCCTC
TCCCT 
HindIII_FUS453X-Tev-His6_R 
Sigma TTTTAAGCTTTCAGTG
ATGATGATGATGATGG
CTTTGGAAATACAGAT
TTTCGCCATCTGGTTT
AGGGGCCTTACA 
XhoI_FUS_F 
Sigma AAAACTCGAGATGGCC
TCAAACGATTATACCC
AAC 
FUS 454_NcoI_F 
Sigma GATACCATGGGCCCA
GGAGGGGGACCAGGT
GG 
P45 Sigma AATTTAATACGACTCACTATAG 
P132 
Sigma ATTGTTTCGTGATAAT
GTCTCTTATTAGTTGA
AAGAGATTCAGTTATC
CATCTATAGTGAGTCG
TATTAAATT 
TagRFP_AgeI 
Sigma TTTTTACCGGTC 
GCCACCATGGTGTCTA
AGGGCGA 
TagRFP_EcoRV_R Sigma TTTTTGATATCCATTAAGTTTGTGCCCCAGTTT 
TagRFP_SpeI Sigma TTTTTACTAGTCATGGTGTCTAAGGGCGA 
TagRFP_AgeI_R 
Sigma TTTTTACCGGTCCATT
AAGTTTGTGCCCCAGT
TT 
FUS_EcoRV_F 
IDT AATTCGATATCCCATG
GCCTCAAACGATTATA
CCCAACAAG 
FUS_BamHI_R 
IDT CGGGATCCTTAATACG
GCCTCTCCCTGCGATC
C 
FusP525L_BamHI_R Sigma TTTTTGGATCCTTA ATACAGCCTCTC 
MBP_NcoI_F Sigma CGCCACCATGAA AACG 
MBPLinker_Tev_EcoRI 
Sigma GAATTCTGAAATGCCT
TGGAAATACAGATTTT
CCCCGAG 
GTTGTTGTTATTGTTAT
TGTT 
Oligonucleotides 
(UG)10 RNA 
Eurofins UGUGUGUGUG 
UGUGUGUGUG 
 
 
